NCT03611569

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-Japanese and Japanese subjects and in patients with Parkinson's disease

Conditions

• Healthy
• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Lu AF82422	Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
DRUG	Placebo	placebo - concentrate for solution for infusion, single dose

Timeline

• Start date: 2018-07-25
• Primary completion: 2021-07-26
• Completion: 2021-07-26
• First posted: 2018-08-02
• Last updated: 2021-10-12

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study